Dynamic Technology Lab Private Ltd Takes Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Dynamic Technology Lab Private Ltd bought a new stake in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 13,408 shares of the medical equipment provider's stock, valued at approximately $831,000.

A number of other hedge funds also recently added to or reduced their stakes in LNTH. South Dakota Investment Council grew its position in shares of Lantheus by 139.3% in the fourth quarter. South Dakota Investment Council now owns 27,317 shares of the medical equipment provider's stock valued at $1,694,000 after purchasing an additional 15,900 shares during the last quarter. Silverberg Bernstein Capital Management LLC acquired a new stake in shares of Lantheus in the fourth quarter valued at approximately $1,385,000. Boston Partners grew its position in shares of Lantheus by 9.6% in the fourth quarter. Boston Partners now owns 562,125 shares of the medical equipment provider's stock valued at $34,344,000 after purchasing an additional 49,195 shares during the last quarter. Natixis Advisors L.P. boosted its position in Lantheus by 172.8% during the third quarter. Natixis Advisors L.P. now owns 52,530 shares of the medical equipment provider's stock worth $3,649,000 after acquiring an additional 33,273 shares during the last quarter. Finally, American Century Companies Inc. boosted its position in Lantheus by 41.9% during the third quarter. American Century Companies Inc. now owns 1,300,904 shares of the medical equipment provider's stock worth $90,387,000 after acquiring an additional 384,093 shares during the last quarter. 99.06% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of analysts recently issued reports on LNTH shares. B. Riley raised their target price on shares of Lantheus from $95.00 to $99.00 and gave the stock a "buy" rating in a research report on Thursday, April 18th. Truist Financial raised their target price on shares of Lantheus from $82.00 to $96.00 and gave the stock a "buy" rating in a research report on Friday, May 3rd. JMP Securities restated a "market outperform" rating and set a $100.00 target price on shares of Lantheus in a research report on Friday, February 23rd. Mizuho raised their target price on shares of Lantheus from $90.00 to $100.00 and gave the stock a "buy" rating in a research report on Friday, May 3rd. Finally, StockNews.com lowered shares of Lantheus from a "buy" rating to a "hold" rating in a research report on Friday, May 3rd. Two analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $99.17.

Lantheus Trading Down 2.9 %

Shares of LNTH stock traded down $2.34 during mid-day trading on Thursday, reaching $79.00. The company's stock had a trading volume of 817,600 shares, compared to its average volume of 1,044,330. The company's 50 day simple moving average is $66.81 and its 200-day simple moving average is $63.96. Lantheus Holdings, Inc. has a 12-month low of $50.20 and a 12-month high of $99.01. The company has a quick ratio of 4.55, a current ratio of 4.84 and a debt-to-equity ratio of 0.59. The firm has a market capitalization of $5.48 billion, a PE ratio of 12.06 and a beta of 0.52.

Lantheus (NASDAQ:LNTH - Get Free Report) last issued its earnings results on Thursday, May 2nd. The medical equipment provider reported $1.51 EPS for the quarter, beating analysts' consensus estimates of $1.40 by $0.11. Lantheus had a net margin of 33.72% and a return on equity of 54.10%. The business had revenue of $369.98 million for the quarter, compared to the consensus estimate of $349.46 million. On average, research analysts predict that Lantheus Holdings, Inc. will post 5.96 EPS for the current fiscal year.

Insider Activity

In other news, major shareholder Lantheus Alpha Therapy, Llc purchased 60,431,039 shares of the company's stock in a transaction that occurred on Wednesday, March 6th. The shares were purchased at an average price of $0.95 per share, with a total value of $57,409,487.05. Following the purchase, the insider now directly owns 116,773,394 shares of the company's stock, valued at approximately $110,934,724.30. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other Lantheus news, CAO Andrea Sabens sold 341 shares of the firm's stock in a transaction on Monday, May 13th. The shares were sold at an average price of $76.89, for a total transaction of $26,219.49. Following the completion of the transaction, the chief accounting officer now directly owns 62,898 shares of the company's stock, valued at approximately $4,836,227.22. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, major shareholder Lantheus Alpha Therapy, Llc acquired 60,431,039 shares of the firm's stock in a transaction on Wednesday, March 6th. The shares were bought at an average cost of $0.95 per share, with a total value of $57,409,487.05. Following the completion of the acquisition, the insider now owns 116,773,394 shares in the company, valued at $110,934,724.30. The disclosure for this purchase can be found here. In the last 90 days, insiders have sold 94,545 shares of company stock valued at $6,177,295. Company insiders own 2.10% of the company's stock.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.